Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

electroCore to Announce First Quarter 2019 Financial Results on Tuesday, May 14

May 8, 2019 at 4:15 PM EDT
Conference Call to be Held at 4:30pm Eastern Time

BASKING RIDGE, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report first quarter ended March 31, 2019 financial results after the close of the market on Tuesday May 14, 2019.  Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.

Tuesday, May 14 @ 4:30pm Eastern Time
Domestic:             877-407-4018
International:             201-689-8471
Conference ID:             13690296

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s current indications are for the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.

For more information, visit

Hans Vitzthum
LifeSci Advisors
(+1) 617-535-7743


Media Contact:
Sara Zelkovic
LifeSci Public Relations
(+1) 646-876-4933